Den går da fuldstændig amok!
Some investors are hinting that it might be up 900% due to a short squeeze. The company has 34.95M outstanding shares with a float of 24.59M shares and only 65k volume in the last 3 months. A very low float can cause the stock to skyrocket.
Now, you’re asking what caused people to buy if there’s no news?
Well, one poster on the Yahoo Finance Board posted;
“In 2011, CytRx sold the rights to arimoclomol to Orphazyme A/S (formerly Orphazyme ApS) in exchange for a one-time, upfront payment of $150,000 (USD) and the right to receive up to a total of $120 million (USD) in milestone payments upon the achievement of certain pre-specified regulatory and business milestones, as well as royalty payments based on a specified percentage of any net sales of products derived from arimoclomol. Orphazyme, a public company trading on the Nasdaq Copenhagen exchange, is testing arimoclomol in three additional indications beyond ALS, including Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM). Orphazyme anticipates announcing top-line results for their pivotal Phase 2/3 trial in NPC during 2018, and if positive, expects to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration and a Marketing Authorization Application (MAA) to the Europeans Medicines Agency (EMA) during the second half of 2019”
Yahoo Finance Board User
Although its reported that, They failed their Phase 1 for the treatment of ALS, its reported that the PDUFA date for Niemann-Pick is June 17, 2021. They are pivoting towards Niemann-Pick.
In January 2019, the medication narrowly missed its first primary objective in a 50-person Phase II/III NPC research study. The severity of the condition was reduced by 74%, and the p-value was 0.0506. Disease development slowed in individuals over the age of 4 and in children who had been receiving an Actelion medicine, which is sometimes prescribed for the disease, according to two pre-specified subgroup analyses. However, the business did not reveal any data for this round of ALS trials, putting the public in the dark about how it performed in the experiment.
The company said in a statement that topline data will be provided during the virtual European Network to Cure ALS meeting from May 12-14, while detailed data will be released later in the year.
Au. Da har vel Orphazyme misset på alle 3 skuddene de hadde på mål, og er vel sånn sett «ferdig»
Ingen penger og ingen dokumenterbare prosjekter så spøker det ja.
Ny base case fra Redeye 15DK, Bear Case 0Dk…
Biotek er binært…
Og alligevel har man kunne lave 100 % hvis man havde mod til det i morges de første 700000 aktier kostede 22-26 kr…
Her er det nok tradere som kjører opp aksjen for å komme ut på en gunstig kurs. Jeg blir forbløffet om denne står over 30 om en uke etter alle bomskuddene dette halvåret.
Ja jeg havde heller ikke set den over 30 i dag, men den bliver kørt op.
også er det hele USA delen de får godt nok omsat nogle aktier.